Alpha2EQ

Astaria Global, based in the US, specializes in advanced therapeutic solutions for equine health, focusing on innovative treatments for lameness, inflammation, and injuries in horses. Alpha2EQ dba Astaria Global designs therapeutic solutions to improve equine health. The company is headquartered in Houston, US and founded in 2018 by Bill Cramer. In April 2025, CIMA Animal Health, a portfolio company of Incline Equity Partners, acquired Astaria Global, Limited Liability Company.

Astaria Global’s core product offering is Alpha2EQ, an advanced therapeutic solution designed to address equine lameness, joint inflammation, soft tissue injury, and airway inflammation. Utilizing patented AlphaActive filtration technology, Alpha2EQ functionally isolates alpha-2-macroglobulin from the horse’s own blood through a two-step centrifugation process. This drug-free treatment is particularly advantageous for veterinarians and horse owners, as it poses no clearance concerns and can be processed conveniently on-site. The multi-dose kit allows for multiple sites of administration during a single visit and can be frozen for up to 12 months, enhancing its usability and accessibility.

The primary clientele includes veterinarians, horse trainers, and owners, primarily operating within North America and select international markets where equine health innovations are sought after. Astaria Global’s revenue structure is based on the direct sale of their flagship product, Alpha2EQ, to veterinarians and equine health specialists. Transactions typically occur through direct orders made by practitioners who utilize the product for treating equine patients, thereby ensuring a direct-to-consumer model. The company’s multi-dose kit format facilitates bulk purchases for clinics, promoting efficient treatment protocols for multiple horses simultaneously.

This transaction model fosters partnerships with veterinary practices, ensuring steady demand for their innovative product offerings. Pricing specifics are established to reflect the value of the effective treatment Alpha2EQ provides in the equine health market, catering to the diverse needs of their customer base. Astaria Global plans to leverage its recent acquisition by CIMA Animal Health to enhance its treatment technology solutions. While no specific new products are mentioned, the acquisition aligns with growth initiatives aimed at expanding their technological capabilities.

The company aims to strengthen its market presence in North America and explore new international markets, although specific regions and timelines are not detailed.